EMA recommends Gilead Sciences' Lenacapavir for HIV prevention, with FDA approval and generic options available soon.

An epidemic that's been sustained for 44 years might finally be quelled, with the milestone approval of the first HIV drug ...

Pre-exposure prophylaxis (PrEP), as an effective means to reduce new HIV infections in high-risk populations, is listed as ...

Last year, studies suggested that lenacapavir, already used to treat people with HIV, was nearly 100% effective in stopping ...

It was supposed to be a banner year in the fight against the HIV epidemic. Nationwide infection rates were gradually falling, ...

The EU has approved an injectable HIV drug offering a two-month dosage schedule, marking a breakthrough in treatment ...

Last year, studies suggested that lenacapavir, already used to treat people with HIV, was nearly 100% effective in stopping ...

Gilead Sciences ( ($GILD) ) has risen by 7.31%. Read on to learn why. Gilead Sciences has seen a notable increase in its ...

The FDA has approved the first 100% effective HIV prevention drug, lenacapavir, set to be distributed globally and potentially save millions of lives.